Conestat alfa

Summary

Conestat alfa is a recombinant human C1‑esterase inhibitor (rhC1‑INH) approved for intravenous use in the treatment of acute hereditary angioedema (HAE) attacks. It replaces deficient C1‑INH, thereby restoring regulation of the complement, kallikrein‑kinin, fibrinolytic and coagulation pathways that underlie bradykinin‑mediated swelling. Clinical investigations have also explored its use during prodromal symptoms and as a prophylactic agent to prevent attacks.

Mechanism of Action

C1‑esterase inhibitor is a serpin that controls activation of the complement cascade (C1 complex), the contact system (factor XIIa, plasma kallikrein), and the fibrinolytic pathway (plasmin). In HAE, deficiency of C1‑INH leads to unchecked kallikrein activity and excess bradykinin, causing vascular permeability and edema. Conestat alfa supplies functional C1‑INH, re‑establishing inhibition of these proteases, reducing bradykinin generation and downstream inflammatory signaling.

What the Research Shows

A 2025 case‑crossover study in five HAE‑C1‑INH type 1 patients showed that intravenous conestat alfa given during a well‑defined prodrome was as effective at preventing progression to swelling as treatment of an established attack, and it reversed prodrome‑associated transcriptomic signatures. A phase II randomized, placebo‑controlled trial reported that twice‑weekly or once‑weekly prophylactic dosing reduced attack frequency in adults and adolescents. A systematic review of randomized trials (up to 2012) found that conestat alfa, compared with placebo, shortened time to symptom relief and had a safety profile comparable to placebo, though direct head‑to‑head comparisons with other agents were lacking.

Reported Benefits

Clinical data indicate that conestat alfa rapidly alleviates acute HAE attacks, shortening time to symptom relief relative to placebo. It appears equally effective when administered at the prodrome stage, potentially averting full attacks. Phase II prophylaxis trials suggest that regular dosing can lower attack frequency, offering an alternative to plasma‑derived C1‑INH. The recombinant origin eliminates risk of blood‑borne pathogen transmission.

Limitations of the Evidence

Evidence is limited by small sample sizes, especially the prodrome study (n=5) and the phase II prophylaxis trial. No large phase III prophylaxis trials have been published, and head‑to‑head comparisons with other HAE therapies are absent. Heterogeneity among studies hampers definitive conclusions about optimal dosing frequency, long‑term safety, and comparative efficacy. Pediatric data are sparse.

Safety Considerations

Across randomized trials, conestat alfa’s adverse‑event profile was similar to placebo, with no serious safety signals reported. The recombinant production process avoids the risk of viral transmission associated with plasma‑derived products. Reported tolerability is comparable to other approved HAE agents, but comprehensive long‑term safety data remain limited, and clinicians should monitor for typical infusion‑related reactions.

How It Is Administered

Conestat alfa is supplied as a sterile solution for intravenous infusion. Dosing is weight‑based (e.g., 50 IU per kilogram, up to a maximum dose) and administered as a single infusion during an acute attack or prodrome, or on a regular schedule for prophylaxis, according to prescribing information.

Routes of Administration

Goals & Uses

• Acute hereditary angioedema attack treatmentTherapeuticHigh
• Treatment of acute HAE attacksTherapeuticHigh
• Reduction of bradykinin-mediated edemaTherapeuticHigh
• Complement pathway regulationMechanisticHigh
• Prophylaxis of HAE attacksTherapeuticLow

Contraindications

• Rabbit allergyHypersensitivityHigh
• Hypersensitivity to conestat alfa or any excipientsAllergyHigh
• Hypersensitivity to conestat alfa or excipientsHypersensitivityHigh

Adverse Effects

• Thrombotic eventsCardiovascularRare
• Infusion‑related reactions (e.g., erythema, flushing)GeneralUncommon
• Hypersensitivity / anaphylaxisImmunologicalRare
• HeadacheNeurologicCommonPain in the head or upper neck
• Injection/infusion site reactionsLocalUncommon
• NauseaGastrointestinalCommonFeeling of sickness or urge to vomit
• DizzinessNeurologicUncommonFeeling faint, lightheaded, or unsteady

Drug Interactions

• ACE inhibitorsModerate
• tPA (tissue plasminogen activator)Moderate

Population Constraints

• PregnancyReproductive SafetyRelative
• Children <1 year of ageAgeAbsolute
• BreastfeedingReproductiveRelative
• Pediatric patients under 13 yearsAgeRelative
• Renal or hepatic impairmentOrgan DysfunctionRelative

Regulatory Status

• European UnionApprovedApproved: Acute treatment of hereditary angioedema attacks in patients with C1‑INH deficiencyEMA‑approved; same indication as US.
• United StatesApprovedApproved: Acute treatment of hereditary angioedema attacks in patients with C1‑INH deficiencyFDA‑approved; prescription‑only.
• United KingdomApprovedApproved: Treatment of acute attacks of hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency in adults and adolescents (≥13 years)Retains approval in UK post-Brexit under MHRA; same indications as EU approval.

FDA‑approved (2017) for acute HAE attacks; also approved by EMA. Administered IV; dosage based on body weight (20 U/kg).

Evidence & Sources

• Clinical response and corresponding blood transcriptome pathways before and after treatment of hereditary angioedema prodromes compared to active swelling attacks
  Journal ArticleModerateGhosh D, et al.2025-01-01T00:00:00.000000Z
• Recombinant human C1 esterase inhibitor (Conestat alfa) for prophylaxis to prevent attacks in adult and adolescent patients with hereditary angioedema
  Journal ArticleModerateValerieva A, Caccia S, Cicardi M2018-01-01T00:00:00.000000Z
• New Treatments for Hereditary Angioedema
  Journal ArticleModerateJohnson NM, Phillips MA2018-01-01T00:00:00.000000Z
• Current and emerging management options for hereditary angioedema in the US
  Journal ArticleModerateEpstein TG, Bernstein JA2008-01-01T00:00:00.000000Z
• [Administration of conestat alfa, human C1 esterase inhibitor and icatibant in the treatment of acute angioedema attacks in adults with hereditary angioedema due to C1 esterase inhibitor deficiency. Treatment comparison based on systematic review results]
  Journal ArticleHighKawalec P, et al.2013-01-01T00:00:00.000000Z

Frequently Asked Questions